Study confirms efficacy of BAK-free drops


Preservative-free travoprost shows equivocal IOP lowering at 1 year after changing therapy

Glaucoma patients who switched from latanoprost, which is preserved with benzalkonium chloride, to BAK-free travoprost had fewer ocular surface complications 1 year later, but experienced no adverse effect on intraocular pressure, according to a recent study.1

In previous studies, OSD index scores improved when clinicians switched patients from preserved to non-preserved drops, but the longest follow-up period was 3 months. With this in mind, Dr Makoto Aihara, PhD, of the University of Tokyo, and colleagues wanted to determine the efficacy and tolerability of BAK-free travoprost (Travatan Z, Alcon) 1 year after changing therapy.

At follow-up visits, the investigators assessed these three outcomes: conjunctival hyperaemia; superficial punctate keratitis (SPK); and IOP.

Conjunctival hyperaemia

This is the most common complication related to use of prostaglandin analogues. The researchers used a 4-grade photographic scale of slight, mild, moderate and severe to measure conjunctival hyperaemia.

Conjunctival hyperaemia at baseline was grade 0 in 55 eyes, grade 1 in 11 eyes, and grade 2 in one eye. Although no significant change occurred immediately, hyperaemia at 3 months was grade 0 in 64 eyes, grade 1 in two eyes and grade 2 in one eye. By 12 months, hyperaemia was grade 0 in 64 eyes, and grade 1 in three eyes.

Incidence of SPK

The researchers detected SPK by fluorescein staining observed with a blue-free filter and by using the AreaDensity (AD) classification (scores ranging from 0 to 6). Thirty-six of the 67 eyes (54%) showed evidence of SPK at baseline. The A1D1 score was slight in 25 eyes and mild (A1D2 or A2D1) to severe (A3D2) in the remaining 11 eyes. The study reported fewer cases of SPK at 1 and 3 months, being present in nine of 67 eyes (13%). The researchers classified the SPK as slight in seven eyes and mild in two eyes. One year after the medication switch, SPK was present in 19 eyes (28%). The SPK was classified as slight (A1D1) in 17 eyes and mild (A1D2) in two eyes.

"The fact that the SPK greater than A1D1 improved within 1 month of treatment with BAK-free travoprost, and that the improved corneal condition was sustained for 12 months is noteworthy," the study stated. "However, there were patients with slight SPK (A1D1) throughout the observation period and their number increased at 12 months, compared with 1 or 3 months."

Measurable IOP decline

Mean IOP, measured with Goldmann applanation tonometry, significantly decreased after the transition to BAKfree travoprost and over the course of the trial. It went from 14.9 mmHg at baseline to 14.3 mmHg at 1 month, 13.9 mmHg at 3 months and back to 14.3 mmHg at 12 months. Although travoprost reduced IOP more than latanoprost, the researchers urged caution in evaluating these results because the additional reduction was less than 1 mmHg.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.